

Company Information

Biotest Pharmaceuticals Corporation Receives FDA Warning Letter

Boca Raton, Florida December 4, 2014 – Biotest Pharmaceuticals Corporation (Biotest), a wholly-owned subsidiary of Biotest AG (Dreieich, Germany), has received a Warning Letter from the U.S. Food and Drug Administration (FDA) relating to an inspection at its Boca Raton location conducted in August 2014. The Warning Letter pertains to the FDA investigator's observations of deviations from current good manufacturing practice requirements. The warning letter does not prevent the manufacturing or distribution of any of BPC's products.

Biotest takes all correspondence from the FDA seriously and will submit its response to the FDA that outlines its plan to resolve all issues included in the letter within the specified timeline. Biotest is fully committed to working closely with the FDA to address and resolve all outstanding concerns related to the letter.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest AG

Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG, researches, develops and manufactures biotherapeutic products with a specialization in immunology and hematology. BPC is a leader in the collection of source plasma and is currently involved in the development of plasma protein products and various hyperimmune (IG) products. The Company owns and manages sixteen plasmapheresis centers across the United States and a state-of-the-art manufacturing facility in Boca Raton, Florida. The Company employs more than 900 people in the U.S.

Contact

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Dr. Monika Buttke
tel.: +49 (0) 6103 801-4406, e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart